Connect public, paid and private patent data with Google Patents Public Datasets

Materials and method for detecting interaction of cftr polypeptides

Info

Publication number
WO2001025421B1
WO2001025421B1 PCT/US2000/027900 US0027900W WO2001025421B1 WO 2001025421 B1 WO2001025421 B1 WO 2001025421B1 US 0027900 W US0027900 W US 0027900W WO 2001025421 B1 WO2001025421 B1 WO 2001025421B1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
invention
cftr
subject
methods
concerns
Prior art date
Application number
PCT/US2000/027900
Other languages
French (fr)
Other versions
WO2001025421A2 (en )
WO2001025421A3 (en )
Inventor
John L Teem
Original Assignee
Univ Florida State Res Found
John L Teem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/564Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712Cystic fibrosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6888Hybridisation probes for detection or identification of organisms
    • C12Q1/6895Hybridisation probes for detection or identification of organisms for plants, fungi, or algae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/20Detection means characterised by being a gene reporter based analysis
    • C12Q2565/201Two hybrid system

Abstract

The subject invention concerns materials and methods for detecting the interaction of CFTR proteins. In one embodiment, the method can be used to determine whether one CFTR polypeptide interacts with a second CFTR polypeptide. The subject invention also concerns materials and methods for screening for drugs or compositions that can restore or enhance interaction of CFTR proteins containing mutation(s) that reduce or prevent dimerization of the proteins. The assay of the present invention can be used to screen a large number of compounds in a high throughput format. The subject invention also pertains to host cells useful in the methods of the invention. The subject invention also concerns compositions and methods for treating patients afflicted with cystic fibrosis.
PCT/US2000/027900 1999-10-06 2000-10-06 Materials and method for detecting interaction of cftr polypeptides WO2001025421B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US15799699 true 1999-10-06 1999-10-06
US60/157,996 1999-10-06
US18189200 true 2000-02-11 2000-02-11
US60/181,892 2000-02-11
US18237300 true 2000-02-14 2000-02-14
US60/182,373 2000-02-14

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10089875 US7238474B1 (en) 1999-10-06 2000-10-06 Materials and methods for detecting interaction of CFTR polypeptides
US11821812 US8288107B2 (en) 1999-10-06 2007-06-25 Materials and methods for detecting interaction of CFTR polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11821812 Continuation US8288107B2 (en) 1999-10-06 2007-06-25 Materials and methods for detecting interaction of CFTR polypeptides

Publications (3)

Publication Number Publication Date
WO2001025421A2 true WO2001025421A2 (en) 2001-04-12
WO2001025421A3 true WO2001025421A3 (en) 2001-08-30
WO2001025421B1 true true WO2001025421B1 (en) 2001-09-27

Family

ID=27388112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027900 WO2001025421B1 (en) 1999-10-06 2000-10-06 Materials and method for detecting interaction of cftr polypeptides

Country Status (2)

Country Link
US (2) US7238474B1 (en)
WO (1) WO2001025421B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968987A4 (en) * 2013-03-15 2017-04-26 Vertex Pharma Correctors acting through msd1 of cftr protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543399A (en) 1989-08-22 1996-08-06 Hsc Research & Development Limited Partnership Cystic fibrosis transmembrane conductance regulator (CFTR) protein
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5939536A (en) 1990-03-05 1999-08-17 Genzyme Corporation Methods for purifying cystic fibrosis transmembrane conductance regulation
CA2037478A1 (en) 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
US5981714A (en) 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
US7118911B1 (en) 1990-03-05 2006-10-10 Genzyme Corporation DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator
US5674898A (en) 1990-03-05 1997-10-07 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1994025607A1 (en) 1993-04-23 1994-11-10 University Of Iowa Research Foundation Method of assaying for drugs which restore function of mutant cftr protein
EP0959877A4 (en) 1996-04-10 2000-08-23 Univ California Correction of genetic defects using chemical chaperones
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6316223B1 (en) * 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system

Also Published As

Publication number Publication date Type
US20080167259A1 (en) 2008-07-10 application
US8288107B2 (en) 2012-10-16 grant
WO2001025421A2 (en) 2001-04-12 application
WO2001025421A3 (en) 2001-08-30 application
US7238474B1 (en) 2007-07-03 grant

Similar Documents

Publication Publication Date Title
Raman et al. Quantitative comparison and evaluation of two commercially available, two‐dimensional electrophoresis image analysis software packages, Z3 and Melanie
Srebalus Barnes et al. Resolving isomeric peptide mixtures: a combined HPLC/ion mobility-TOFMS analysis of a 4000-component combinatorial library
WO2000044092A1 (en) Vibrator and electronic device with vibrator
Wada et al. Structure elucidation of hemoglobin variants and other proteins by digit‐printing method
Osmulski et al. Atomic force microscopy reveals two conformations of the 20 S proteasome from fission yeast
Song et al. Calcium-and pH-dependent aggregation of carboxypeptidase E
WO1998026090A1 (en) Method of determining cholesterol content of high-density lipoproteins
Kvassman et al. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1
Neubert et al. Affinity capillary electrophoresis in pharmaceutics and biopharmaceutics
WO2000071743A1 (en) Two-hybrid method in mammalian cell
WO1998053064A1 (en) Organic anion transporter and gene coding for the same
Böhm et al. Was läßt sich aus der molekularen Erkennung in Protein‐Ligand‐Komplexen für das Design neuer Wirkstoffe lernen?
Xue et al. Comparison of the effects of Apo (a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein (a) with regulatory molecules
WO1998038304A1 (en) Novel polypeptide, dna encoding the same and use thereof
Pazdernik et al. An analysis of suppressor mutations suggests that the two halves of the lactose permease function in a symmetrical manner
OKAMOTO et al. Certified reference material program at National Institute for Environmental Studies
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2002046409A3 (en) Proteins and nucleic acids encoding same
Bouchon et al. Letter to the editors
Loo et al. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates
Wang et al. Analysis of substrate-binding elements in OxlT, the oxalate: formate antiporter of Oxalobacter formigenes
Payne et al. Second virial coefficient determination of a therapeutic peptide by self‐interaction chromatography
EP1089118A3 (en) Electrophoretic display and method of making the same
Bures et al. Identification of incompletely processed potential carboxypeptidase E substrates from CpEfat/CpEfat mice
Bunk Characterization of the glycation of albumin in freeze-dried and frozen human serum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP